EnteroMedics Announces PMA Application for VBLOC Therapy in Obesity Accepted for Review and Filing by FDA

EnteroMedics Inc. (NASDAQ: ETRM ), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Premarket Approval (PMA) application for approval of the Maestro® Rechargeable System's